Cite
Csákváry V, Ammer N, Bagci EB, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial. Horm Res Paediatr. 2021;94(7):239-250doi: 10.1159/000519232.
Csákváry, V., Ammer, N., Bagci, E. B., Bolshova, O. V., Damholt, B. B., Katanic, D., Mikhailova, E., Muzsnai, �. �., Raduk, D., Senatorova, G., Szalecki, M., Teifel, M., Vajda, Z., Zelinska, N., & Chaychenko, T. (2021). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial. Hormone research in paediatrics, 94(7), 239-250. https://doi.org/10.1159/000519232
Csákváry, Violetta, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial." Hormone research in paediatrics vol. 94,7 (2021): 239-250. doi: https://doi.org/10.1159/000519232
Csákváry V, Ammer N, Bagci EB, Bolshova OV, Damholt BB, Katanic D, Mikhailova E, Muzsnai Á, Raduk D, Senatorova G, Szalecki M, Teifel M, Vajda Z, Zelinska N, Chaychenko T. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macimorelin in Children with Suspected Growth Hormone Deficiency: An Open-Label, Group Comparison, Dose-Escalation Trial. Horm Res Paediatr. 2021;94(7):239-250. doi: 10.1159/000519232. Epub 2021 Aug 26. PMID: 34438400.
Copy
Download .nbib